Fighting retinal blindness SPAIN. Report 3: Clinical outcomes of vascular endothelial growth factor inhibitors in low vision eyes with neovascular age-related macular degeneration. A national database study

Heier JS, Brown DM, Chong V, Korobelnik J, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF-Trap-Eye) for wet age-related macular degeneration. Ophthalmology. 2012;119:2537–48. https://doi.org/10.1016/j.ophtha.2012.09.006.

Article PubMed Google Scholar

Martin DF, Ying G, Grunwald JE, Jaffe GJ. Ranibizumab and bevacizumab in neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–908. https://doi.org/10.1056/NEJMOA1102673/SUPPL_FILE/NEJMOA1102673_DISCLOSURES.PDF.

Article CAS PubMed Google Scholar

Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31. https://doi.org/10.1056/NEJMoa054481.

Article CAS PubMed Google Scholar

Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin in neovascular age-related macular degeneration. N Engl J Med 2006;355:1432–44. https://doi.org/10.1056/NEJMoa062655.

Article CAS PubMed Google Scholar

Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for the treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388–98. https://doi.org/10.1016/j.ophtha.2012.03.053.

Article PubMed Google Scholar

Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, et al. Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration: one-year results from the randomized IVAN trial. Ophthalmology. 2012;119:1399–411. https://doi.org/10.1016/j.ophtha.2012.04.015.

Article PubMed Google Scholar

Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularization: 2-year results from the IVAN randomized controlled trial. Lancet. 2013;382:1258–67. https://doi.org/10.1016/S0140-6736(13)61501-9.

Article CAS PubMed Google Scholar

Ho AC, Busbee BG, Regillo CD, Heier JS, Lindstrom RL, Orr SC, et al. 24-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014;121:2181–92. https://doi.org/10.1016/J.OPHTHA.2014.05.009.

Article PubMed Google Scholar

Busbee BG, Ho AC, Brown DM, Heier JS, Suñer IJ, Li Z, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120:1046–56. https://doi.org/10.1016/J.OPHTHA.2012.10.014.

Article PubMed Google Scholar

Bressler NM, Doan QV, Varma R, Lee PP, Suñer IJ, Dolan C, et al. Estimated cases of blindness and visual impairment avoided by the use of ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration. Arch Ophthalmol (Chic, Ill 1960). 2011;129:709–17. https://doi.org/10.1001/ARCHOPHTHALMOL.2011.140.

Article Google Scholar

Zarranz-Ventura J, Parrado-Carrillo A, Nguyen V, Sararols L, Garay-Aramburu G, Puzo M, et al. Creation of a national database on neovascular age-related macular degeneration using a web-based platform: fighting retinal blindness Spain. Report 1: Visual outcomes. Clin Exp Ophthalmol. 2022;50:312–24. https://doi.org/10.1111/CEO.14054.

Article PubMed Google Scholar

Ozawa Y, Veritti D, Sarao V, Soppelsa V, Danese C, Chhablani J, et al. Clinical medicine for the treatment of neovascular age-related macular degeneration in clinical practice: systematic review, meta-analysis, and meta-regression. J Clin Med. 2022. https://doi.org/10.3390/jcm11020325.

Martin-Pinardel R, Izquierdo-Serra J, De Zanet S, Parrado-Carrillo A, Garay-Aramburu G, Puzo M, et al. Artificial intelligence-based fluid quantification and associated visual outcomes in a real-world, multicenter national database of neovascular age-related macular degeneration. Br J Ophthalmol. 2024;108:253–62. https://doi.org/10.1136/bjo-2022-322297.

Article PubMed Google Scholar

Recommendations | Age-related macular degeneration | Guidance | NICE.

Yeung L, Hsieh YT, Yang CH, Chen LJ, Chen SJ, Cheng CK, et al. Treatment of neovascular age-related macular degeneration: Taiwanese expert consensus. J Formos Med Assoc. 2021;120:2061–71. https://doi.org/10.1016/J.JFMA.2021.06.012.

Article PubMed Google Scholar

Gillies MC, Walton R, Liong J, Arnold JJ, McAllister I, Moriet N, et al. Efficiently collecting high-quality data on treatment outcomes in macular disease: the “Fight Retina Blindness!” project. Retina. 2014;34:188–95. https://doi.org/10.1097/IAE.0b013e318296b271.

Article PubMed Google Scholar

Lange C, Feltgen N, Junker B, Schulze-Bonsel K, Bach M. Resolution of the clinical visual acuity categories “hand movement” and “finger counting” using the Freiburg Visual Acuity Test (FrACT). Graefes Arch Clin Exp Ophthalmol. 2009;247:137–42. https://doi.org/10.1007/s00417-008-0926-0.

Article CAS PubMed Google Scholar

Shona O, Gupta B, Vemala R, Sivaprasad S. Visual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline visual acuity. Clin Exp Ophthalmol. 2011;39:5–8. https://doi.org/10.1111/J.1442-9071.2010.02424.X.

Article PubMed Google Scholar

Rahimy E, Rayess N, Ho AC, Regillo CD. Treatment outcomes for patients with neovascular age-related macular degeneration with baseline vision better than 20/40 using a treat-and-extend regimen. Retina. 2016;36:875–80. https://doi.org/10.1097/IAE.0000000000000814.

Article CAS PubMed Google Scholar

Langelaan M, De Boer MR, Van Nispen RMA, Wouters B, Moll AC, Van Rens GHMB. Impact of visual impairment on quality of life: a comparison with quality of life in the general population and with other chronic diseases. Ophthalmic Epidemiol. 2007;14:119–26. https://doi.org/10.1080/09286580601139212.

Article PubMed Google Scholar

Fenwick EK, Ong PG, Man REK, Cheng CY, Sabanayagam C, Wong TY, et al. Association between visual impairment and major ocular disease and mobility and independence in a Chinese population. JAMA Ophthalmol. 2016;134:1087–93. https://doi.org/10.1001/JAMAOPHTHALMOL.2016.2394.

Article PubMed Google Scholar

Veritti D, Sarao V, Soppelsa V, Danese C, Chhablani J, Lanzetta P. Treatment of neovascular age-related macular degeneration in clinical practice: systematic review, meta-analysis, and meta-regression. J Clin Med. 2022;11. https://doi.org/10.3390/JCM11020325.

Gillies MC, Campain A, Barthelmes D, Simpson JM, Arnold JJ, Guymer RH, et al. Long-term outcomes of treatment for neovascular age-related macular degeneration. Ophthalmology. 2015;122:1837–45. https://doi.org/10.1016/j.ophtha.2015.05.010.

Article PubMed Google Scholar

Tufail A. The neovascular age-related macular degeneration database: multicenter study of 92,976 ranibizumab injections: report 1: visual acuity manuscript no. 2013-568. Ophthalmology. 2014;121:1092–101. https://doi.org/10.1016/j.ophtha.2013.11.031.

Article Google Scholar

Zarranz-Ventura J, Liew G, Johnston RL, Xing W, Akerele T, McKibbin M, et al. The neovascular age-related macular degeneration database: report 2: incidence, treatment, and visual outcomes of the second treated eye. Ophthalmology. 2014;121:1966–75. https://doi.org/10.1016/j.ophtha.2014.04.026.

Article PubMed Google Scholar

Izquierdo-Serra J, Martin-Pinardel R, Moll-Udina A, Bernal-Morales C, Garay-Aramburu G, Sanchez-Monroy J, et al. Influence of macular neovascularization on the outcomes of intravitreal anti-VEGF therapy in age-related macular degeneration. Ophthalmol Retin. 2024;8:350–9. https://doi.org/10.1016/j.oret.2023.10.022.

Article Google Scholar